hil-214

Vaccineexperimental

Clinical trial activity

4 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
2
Phase 4
0

Earliest trial started Mar 16, 2022 (NCT05281094)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • NorovirusImmunity, active

    immunity, active - norovirus

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06007781Phase 1Aug 18, 2023HilleVax
NCT05972733Phase 2Aug 2, 2023HilleVax
NCT05836012Phase 2/Phase 3 (Phase 3)Jun 2, 2023HilleVax
NCT05281094Phase 2/Phase 3 (Phase 3)Mar 16, 2022HilleVax
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
HilleVaxFor profit4432022
1 organizations
Page 1 / 1